Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract

Hardik D. Patel, Jeffrey M. Chambliss, Meera R. Gupta

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Allergy immunotherapy (AIT) is the only disease-modifying therapy for the treatment of allergic diseases. Although its efficacy and utility are well-established, the potential for serious adverse events, cumbersome and lengthy treatment protocols, and variability of natural allergen preparations have limited its widespread application. Recent advances in recombinant technology have opened new avenues for the development of AIT vaccines. The purpose of this review is to highlight recent evidence on the use of novel recombinant vaccines and review the mechanisms, efficacy, safety, and limitations of AIT. Emerging evidence suggests that recombinant vaccines may provide a viable treatment alternative that improves on the limitations of natural extract therapy while maintaining efficacy.

Original languageEnglish (US)
Article number63
JournalCurrent Allergy and Asthma Reports
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Allergens
Immunotherapy
Hypersensitivity
Synthetic Vaccines
Therapeutics
Clinical Protocols
Vaccines
Technology
Safety

Keywords

  • Adverse effects of immunotherapy
  • Allergy immunotherapy
  • Carrier-bound B cell epitopes
  • Hypoallergenic vaccines
  • Mechanisms of allergen immunotherapy
  • Mechanisms of recombinant allergy immunotherapy
  • Recombinant allergy vaccines
  • T cell epitope therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract. / Patel, Hardik D.; Chambliss, Jeffrey M.; Gupta, Meera R.

In: Current Allergy and Asthma Reports, Vol. 17, No. 9, 63, 01.09.2017.

Research output: Contribution to journalReview article

Patel, Hardik D. ; Chambliss, Jeffrey M. ; Gupta, Meera R. / Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract. In: Current Allergy and Asthma Reports. 2017 ; Vol. 17, No. 9.
@article{429518e2677a435491ea078080c94236,
title = "Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract",
abstract = "Allergy immunotherapy (AIT) is the only disease-modifying therapy for the treatment of allergic diseases. Although its efficacy and utility are well-established, the potential for serious adverse events, cumbersome and lengthy treatment protocols, and variability of natural allergen preparations have limited its widespread application. Recent advances in recombinant technology have opened new avenues for the development of AIT vaccines. The purpose of this review is to highlight recent evidence on the use of novel recombinant vaccines and review the mechanisms, efficacy, safety, and limitations of AIT. Emerging evidence suggests that recombinant vaccines may provide a viable treatment alternative that improves on the limitations of natural extract therapy while maintaining efficacy.",
keywords = "Adverse effects of immunotherapy, Allergy immunotherapy, Carrier-bound B cell epitopes, Hypoallergenic vaccines, Mechanisms of allergen immunotherapy, Mechanisms of recombinant allergy immunotherapy, Recombinant allergy vaccines, T cell epitope therapy",
author = "Patel, {Hardik D.} and Chambliss, {Jeffrey M.} and Gupta, {Meera R.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11882-017-0727-9",
language = "English (US)",
volume = "17",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "9",

}

TY - JOUR

T1 - Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract

AU - Patel, Hardik D.

AU - Chambliss, Jeffrey M.

AU - Gupta, Meera R.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Allergy immunotherapy (AIT) is the only disease-modifying therapy for the treatment of allergic diseases. Although its efficacy and utility are well-established, the potential for serious adverse events, cumbersome and lengthy treatment protocols, and variability of natural allergen preparations have limited its widespread application. Recent advances in recombinant technology have opened new avenues for the development of AIT vaccines. The purpose of this review is to highlight recent evidence on the use of novel recombinant vaccines and review the mechanisms, efficacy, safety, and limitations of AIT. Emerging evidence suggests that recombinant vaccines may provide a viable treatment alternative that improves on the limitations of natural extract therapy while maintaining efficacy.

AB - Allergy immunotherapy (AIT) is the only disease-modifying therapy for the treatment of allergic diseases. Although its efficacy and utility are well-established, the potential for serious adverse events, cumbersome and lengthy treatment protocols, and variability of natural allergen preparations have limited its widespread application. Recent advances in recombinant technology have opened new avenues for the development of AIT vaccines. The purpose of this review is to highlight recent evidence on the use of novel recombinant vaccines and review the mechanisms, efficacy, safety, and limitations of AIT. Emerging evidence suggests that recombinant vaccines may provide a viable treatment alternative that improves on the limitations of natural extract therapy while maintaining efficacy.

KW - Adverse effects of immunotherapy

KW - Allergy immunotherapy

KW - Carrier-bound B cell epitopes

KW - Hypoallergenic vaccines

KW - Mechanisms of allergen immunotherapy

KW - Mechanisms of recombinant allergy immunotherapy

KW - Recombinant allergy vaccines

KW - T cell epitope therapy

UR - http://www.scopus.com/inward/record.url?scp=85027856930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027856930&partnerID=8YFLogxK

U2 - 10.1007/s11882-017-0727-9

DO - 10.1007/s11882-017-0727-9

M3 - Review article

C2 - 28822054

AN - SCOPUS:85027856930

VL - 17

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 9

M1 - 63

ER -